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Abstract
Background: Cardiovascular disease represents the leading cause of morbidity, mortality and graft function loss in renal 
transplant recipients (RTR). Aggressive treatment of risk factors is strongly advocated. However, there is a gap between 
recommended evidence-based therapy and effective cardiovascular management in that population.
Objective: To establish a cardiovascular risk factor control strategy for RTR.
Methods: The cardiovascular risk of 300 RTR of a renal transplant unit was assessed using the Framingham criteria. 
Interventions on modifiable risk factors were suggested to attending physicians by letters attached to patients’ charts, 
including lifestyle modifications, blood pressure control and use of antiplatelet and lipid-lowering therapy. Risk factor 
profiles were re-evaluated after 6 and 12 months.
Results: Most patients were at high cardiovascular risk (58%). After 12 months, the proportion of patients on antiplatelet, 
antihypertensive and lipid-lowering therapy was significantly increased (29 to 51%, 83 to 92% and 3 to 46%, p < 0.001, 
respectively). Total cholesterol and triglyceride levels decreased (237 to 215 mg/dl, p = 0.001 and 244 to 221 mg/dl, p 
= 0.03). Although a non-significant reduction in LDL levels was observed (136 to 116 mg/dl, p = 0.12), patients starting 
statins within the first 6 months of the study presented a significant 25% reduction in LDL (159 to 119 mg/dl, p < 0.001). 
The proportion of patients with complete plasma lipid evaluation was also increased (27% to 49%, p < 0.001).
Conclusion: Our results suggest that a simple, inexpensive strategy significantly improves the cardiovascular risk profile 
of RTR, potentially translating into marked benefits for long-term graft function and life expectancy. (Arq Bras Cardiol. 
2010; [online]. ahead print, PP.0-0)
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role in the development of cardiovascular events after 
renal transplantation and are strongly associated with the 
immunosuppressive therapy. In addition, renal dysfunction-
related risk factors clearly contribute to the development of 
CVD in RTR. 
To prevent post-transplantation CVD it is necessary to 
identify and aggressively treat modifiable risk factors. A basic 
principle of intervention is that the intensity of risk-reduction 
therapy should be adjusted to the absolute individual risk 
of each patient6-7. Primary and secondary cardiovascular 
prevention trials in the general population have documented 
substantial benefits from the administration of statins and 
antiplatelet drugs. Some evidence has supported the use 
of those medications in RTR. However, cardiovascular risk 
management has not been addressed properly in RTR8-12. As 
described for the general population13, it is very likely that 
there is a gap between the cardiovascular care recommended 
in clinical practice guidelines and the effective cardiovascular 
management for RTR. In this study, we established a relatively 
simple strategy to optimize cardiovascular risk factor profile 
evaluation and treatment for RTR followed in a renal 
transplant unit of São Paulo, Brazil.
Introduction
Renal transplant recipients (RTR) are more prone to 
cardiovascular disease (CVD) compared with the general 
population. The incidence of CVD among RTR seems to be 
three to four-fold higher than that observed in age-matched 
control populations1. In fact, CVD is the leading cause of 
morbidity and mortality after renal transplantation and, as 
a consequence of death with functioning graft, represents 
also the major cause of graft function loss in long-term 
RTR1-5. This high CVD incidence is partially explained by 
equally high cardiovascular risk factor prevalence and 
accumulation before and after kidney transplantation. 
Conventional risk factors, mainly hypertension, diabetes 
and hyperlipidemia, play a well-recognized proatherogenic 
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Methods
Sample study
The Hospital do Rim e Hipertensão, a partner of the 
Federal University of São Paulo, performs more than 
five hundred renal transplants per year (656 in 200414). 
Approximately 80% of the recipients are followed at the 
outpatient unit indefinitely. In December 2004, almost 3,000 
patients were registered for follow-up in that outpatient unit, 
where sample selection for this study was performed. All 
patients older than 40 years with stable renal function and 
that had received a kidney at least 12 months before were 
identified. Using these criteria, 909 patients were selected 
and questionnaires, medical records and blood test results 
were used in each case to evaluate cardiovascular risk factors 
and calculate the Framingham Heart Study risk score (FRS). 
HDL was considered to be 50 mg/dl when results were not 
available. Five hundred, sixty-three patients were excluded 
due to incomplete information with respect to elements 
necessary for FRS calculation. During the follow-up, forty-six 
patients were excluded due to several other causes (Figure 
1). The study group consisted of the remaining 300 patients 
who completed 12 months of follow-up. All patients gave 
informed consent to participate in this study, which was 
approved by the local Ethics Committee.
Sample variables
The following variables were collected at the initial 
evaluation: age, gender, cause of end-stage renal 
disease (ESRD), time elapsed since transplantation, prior 
transplantation, and presence of pretransplant diabetes and 
CVD. CVD was defined as ischemic heart disease (IHD), 
peripheral vascular disease (PVD) or cerebrovascular disease. 
IHD included angina pectoris, myocardial infarction, coronary 
artery revascularization by percutaneous balloon-angioplasty 
or bypass grafting, or death as a result of IHD (in the follow-
up). Deaths were considered attributable to IHD if the autopsy 
was consistent with the diagnosis or if the events preceding 
death made IHD the most likely cause. PVD was defined as 
amputation resulting from vascular insufficiency or history of a 
limb revascularization procedure (bypass or endarterectomy). 
Cerebrovascular disease included documented strokes or 
transient ischemic events.
Variables that could present different values throughout 
the study were recorded at the initial evaluation and 6 and 
12 months thereafter: weight, height, body mass index 
(BMI; kg/m2), cigarette smoking status, immunosuppressive 
agent prescription, serum creatinine, total cholesterol (TC), 
triglycerides (TG), high-density lipoprotein cholesterol 
(HDL), low-density lipoprotein cholesterol (LDL), blood 
pressure (mean of the last three measurements) and use 
of antihypertensive, lipid-lowering and antiplatelet agents. 
Diabetes and CVD were also reassessed at 6 and 12 months 
of the study. 
Fasting TC and TG concentrations were determined by 
commercially available standard automated enzymatic assays. 
HDL was evaluated by dextran sulphate precipitation method 
and LDL concentrations were calculated using the Friedewald 
formula. Creatinine clearance (CrCl) was calculated through 
the Cockroft-Gault formula.
Cardiovascular risk
The FRS was calculated for each subject according to NCEP-
ATPIII guidelines6. The Framingham Heart Study provides 
an algorithm to assess the 10-year absolute risk for “hard” 
coronary events (myocardial infarction and coronary artery 
disease-related deaths). Risk was then classified as low (0-9%), 
moderate (10-20%) or high (>20%).
Figure 1 - Eligible and final study sample. Reasons for exclusion before and during follow-up are depicted.
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Cardiovascular risk factor control
After cardiovascular risk classification, objective 
interventions on individual modifiable risk factors, all of them 
based on clinical practice guidelines, were recommended 
to attending physicians by means of formal letters attached 
to each patient’s chart. The interventions included, when 
appropriate: lifestyle modifications (diet and physical activity), 
aggressive blood pressure control (target < 130 x 80 mmHg), 
use of antiplatelet (aspirin) and lipid-lowering therapy. In 
addition, patients who had reported a positive smoking history 
during evaluation were recommended to seek a specialized 
program on smoking cessation located in our Institution. 
Cardiovascular risk factor profiles were then re-evaluated 6 
and 12 months after strategy implementation.
Analysis
Values are reported as means and standard deviations (SD), 
or medians. Analysis of variance for repeated measurements 
was used for comparisons of numerical data. Non-parametric 
analysis for ordinal measurements was used for comparisons 
of categorical data. P < 0.05 was considered significant.
Results
Patient characteristics
Three-hundred patients were followed for 12 months. 
Mean age was 49.9 (6.9) years (median 48), fifty-eight percent 
were men and only 2% had been submitted to more than 
one renal transplant. The mean transplantation time was 56.6 
months (median 49). The cause of ESRD was undetermined in 
40%, hypertension in 24%, chronic glomerulonephritis in 12%, 
diabetes in 11% and autosomal dominant polycystic kidney 
disease in 8% of patients. Immunosuppressive treatment 
at enrollment included, with or without azathioprine or 
mycophenolate, cyclosporine (CsA, 70%), corticosteroid 
(28%), CsA plus corticosteroid (66%), or tacrolimus plus 
corticosteroid (59%). After 12 months there was a slight 
decrease in the proportion of patients taking CsA (to 66%, p 
< 0.001) and the CsA-corticosteroid association (to 64%, p 
= 0.023). No significant change was seen in the remaining 
immunosuppressants prescribed.
FRS cardiovascular risk
At the initial evaluation, according to FRS, one hundred 
and fourteen patients were classified as low, eleven as 
moderate and 175 as high cardiovascular risk. After the strategy 
implementation, a gradual and significant decrease in the low-
risk group patients was observed - to 101 patients at 6 months 
and 90 patients at 12 months (p < 0.001). Conversely, there 
was a significant increase in the high-risk patient group - to 
187 patients at 6 months and 197 patients at 12 months (p 
< 0.001). There were no differences in the moderate risk 
group - 12 and 13 patients at 6 and 12 months, respectively 
(p = 0.48, Figure 2).
Diabetes and CVD
Diabetes was present in 126 patients at the initial 
evaluation. IHD was observed in 51 patients, PVD or 
cerebrovascular disease in 29, and IHD and PVD or 
cerebrovascular association was detected in 6 patients. 
During the 12 months of follow-up there was an increase 
Figure 2 - Patient relative distribution according to Framingham risk score before and after 6 and 12 months of the strategy implementation (N = 300; * p < 0.001 vs baseline).
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in the prevalence of diabetes and atherosclerotic disease. 
Diabetes was present in 133 and 145 patients at 6 and 12 
months, respectively (p < 0.001). IHD was observed in 
61 and 69 patients, PVD or cerebrovascular disease was 
present in 37 and 44 (p < 0.001), and IHD and PVD or CVD 
association was present in 10 and 17 patients in the same 
period (p = 0.003, Figure 3). 
Cardiovascular events
Twenty-two cardiovascular events occurred in 19 patients 
(6%) during the 12 months of follow-up. There were no 
cardiovascular deaths. Ten patients (3%) presented new 
coronary artery disease-related events (5 patients had 
myocardial infarction, three patients had coronary artery 
revascularization by percutaneous balloon-angioplasty and 2 
patients had angina pectoris). Seven patients (2%) had a limb 
amputation resulting from PVD and 5 patients (1.6%) had 
confirmed cerebrovascular ischemic events.
Antihypertensive, lipid-lowering and antiplatelet therapy
At the initial evaluation, two-hundred and forty-nine 
patients were taking antihypertensive drugs, eighty-
seven were on antiplatelet therapy and only 10 patients 
were receiving lipid-lowering drugs. During follow-up, 
a progressive and significant increase was observed in 
the number of patients receiving those medications. 
Antihypertensive drugs were prescribed to 272 patients at 
6 months and to 286 at 12 months (p < 0.001); antiplatelet 
therapy (aspirin) to 136 and 154 (p < 0.001) and lipid-
lowering drugs (statins in all cases) to 110 and 137 patients, 
respectively (p < 0.001, Figure 4). 
Renal function, blood pressure, BMI and lipid profile
There were no differences in BMI or CrCl between baseline 
records and after 6 and 12 months. There was a non-significant 
reduction in systolic and diastolic blood pressure (SBP and 
DBP, respectively). At 6 months of follow-up, the strategy 
implementation resulted in significant decreases in serum 
TC and TG levels. At 12 months, TC decreased even more 
and there was no additional significant reduction in TG level. 
Although only a non-significant reduction in LDL levels was 
observed after 6 and 12 months, in the subgroup of 128 
patients in whom the lipid-lowering therapy was started within 
the first 6 months of the study, we detected a significant 25% 
reduction in LDL levels at 12 months (from 159 to 119 mg/
dl, p < 0.001). A small decrease in HDL levels was observed 
(58.4 to 54.2 after 6 months and 55.6 mg/dl after 12 months, 
p = 0.035, Table 1).
At the initial analysis, lipid profile evaluation (TC, LDL, 
HDL or TG) was available in the medical records of 240 (80%) 
patients. However, dyslipidemia was not properly assessed. 
Eighty patients had a complete lipid profile, whereas the 
majority (160 patients) presented only TC and TG in the 
medical charts. At 6 and 12 months, complete lipid profiles 
were available for a gradually higher number of patients (138 
and 145, respectively, p < 0.001, Figure 5).
Smoking status
At study enrollment, 22 (7%) patients were current smokers. 
Three of them were not directed to the program on smoking 
cessation as recommended. Of the 19 remaining patients 
directed to the program, only 1 sought the recommended 
therapy and successfully quit smoking within 12 months.
Figure 3 - Prevalence of diabetes and atherosclerotic disease at baseline, and 6 and 12 months after strategy implementation. (N = 300; *p = 0.003, **p < 0.001 vs 
baseline). IHD - ischemic heart disease; PVD - peripheral vascular disease; DM - diabetes mellitus.
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Figure 4 - Proportion of patients receiving specific cardiovascular medications before, and 6 and 12 months after strategy implementation (N = 300; *p < 0.001 vs baseline).
Table 1 - Blood pressure, body mass index, renal function and serum lipid levels before and during follow-up
Basal 6 months 12 months p
SBP (mmHg) 136 (13.7) 134.2 (14.2) 135.4 (14.6) 0.139
DBP (mmHg) 82.7 (7.7) 81.8 (7.4) 81.6 (7.9) 0.071
BMI (kg/m2) 26.7 (4.3) 26.8 (4.3) 26.9 (4.5) 0.525
CrCl (ml/min) 60.8 (17.7) 60.5 (18.2) 61.9 (18.9) 0.085
TC (mg/dl) 237.5 (66.8) 222.7 (58.1) 215.1 (55) 0.001
LDL (mg/dl) 136.4 (53.1) 124.7 (41.4) 115.6 (41.7) 0.118
HDL (mg/dl) 58.4 (16.7) 54.2 (15.6) 55.6 (15.7) 0.035
TG (mg/dl) 244.1 (197.3) 218.9 (148.9) 220.8 (232.6) 0.001
SBP - systolic blood pressure; DBP - diastolic blood pressure; BMI - body mass index; CrCl - creatinine clearance; TC - total cholesterol; LDL - low density lipoprotein; 
HDL - high-density lipoprotein; TG - triglycerides.
Discussion
Despite advances in immunosuppressive therapy and 
increments in graft survival, RTR have a significantly reduced 
life expectancy largely due to premature CVD1-5,15. Although 
there is extensive data in the literature concerning the general 
population, there are no specific guidelines for CVD control in 
RTR and interventional trials to demonstrate that modifications 
of traditional risk factors reduce CVD in this population are 
not available. However, it has been recently demonstrated 
that patients with renal function impairment should be 
similarly managed6. In addition there is no evidence at all that 
a patient with renal function impairment should be managed 
differently from an individual in the general population6,13. 
Due to these facts, the American Heart Association, the 
American College of Cardiology and the National Kidney 
Foundation recommend that patients with renal dysfunction 
be seen as high cardiovascular risk individuals and managed 
accordingly2,4,6,7,16-18.
Although widely used, there are some controversies 
about the relevance of FRS calculation in RTR. Nevertheless, 
we used the NCEP-ATP III-modified FRS, as it may help to 
select a high-risk population of RTR4,19. We selected patients 
over the age of 40 years with more than 12 months of renal 
transplant. Hence, younger patients who were therefore less 
exposed to cardiovascular risk factors were not included20. 
The minimum time of 12 months since transplantation was 
adopted as representing enough evaluation and treatment 
time of cardiovascular risk factors by the attending physician 
team. We assumed that these patients were on an established, 
steady situation regarding risk factor control.
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Figure 5 - Proportion of patients presenting incomplete [total cholesterol (TC) and triglycerides (TG) only] and complete (TC, TG, low- and high-density lipoprotein 
cholesterol) lipid profile in the medical charts before, and 6 and 12 months after strategy implementation (N = 300; *p < 0.001 vs corresponding baseline, #p < 0.001 vs 
corresponding 6 months).
The sample studied presented an extremely unfavorable 
risk factor profile, even in the presence of satisfactory and 
stable renal function. Considering the cardiovascular risk 
profile obtained and the time elapsed since transplantation, 
the population studied was receiving less than optimal 
cardiovascular assistance. The majority of patients at the 
beginning of the study were classified as high-risk group. This 
is noteworthy, particularly if we consider that the average age 
of the population was below 50 years. Two factors determined 
the relatively small proportion of patients included in the 
moderate risk group (4%). First, the absence of important 
data in the medical charts, which confirms that, despite the 
availability and easy access to guidelines and evidence-based 
medicine information, cardiovascular risk has yet to become 
a major concern for physicians that treat RTR. Secondly, the 
high prevalence of diabetes and CVD led to a great proportion 
of patients automatically classified as high risk. 
 It is not surprising at all that the proportion of high-risk 
patients did not improve during follow-up (as a matter of fact 
it worsened from 58% to 66% in 12 months). The vast majority 
of high-risk patients were thus classified because they already 
presented, at some point of their lives, atherosclerotic disease 
manifestation and/or diabetes. Even with perfect control of 
blood pressure, cholesterol levels and other risk factors, those 
patients will continue to be classified as high risk. It should also 
be mentioned that FRS calculation is not an appropriate tool to 
detect changes in cardiovascular risk following interventions, 
but rather an aid to guide decisions regarding the nature and 
intensity of therapy6.
The increase in proportion of high-risk patients is also 
expected: it reflects cardiovascular risk status in previous 
years and not only in previous months. Worsening in the risk 
factor profile is strongly associated to renal dysfunction and 
immunosuppressive therapy2,5,21-23. As a significant increase in 
CVD and diabetes prevalence seen in our study was observed 
within a short period of time and renal function remained 
stable throughout the follow-up, the deleterious influence of 
immunosuppressants was probably the predominant factor. 
In fact, most patients received corticosteroids (98%) and CsA 
(70%), drugs clearly linked to the development and aggravation 
of hypertension, diabetes and unfavorable lipid profile. In 
addition, we detected a small, but significant reduction in the 
proportion of patients receiving CsA during the follow-up. This 
was motivated, in general, by chronic graft rejection, further 
exposing those patients to non-traditional risk factors. 
No specific measure to control risk factors has been 
demonstrated so far as capable of “erasing” past exposure 
to risk. In order to detect any improvements in RTR 
cardiovascular risk control, we evaluated their modifiable 
risk factor profile during follow-up. Extensive data in the 
literature indicates that preventive measures, such as the 
administration of aspirin and lipid-level management, result 
in long-term benefits in the general population, reducing 
long-term mortality and morbidity.
Although in the beginning of the study 83% of patients 
were taking antihypertensive drugs, average SBP and DBP 
were above recommended levels. After 12 months, we were 
able to detect a further significant increase in the proportion 
of patients taking antihypertensive drugs (reaching 92%). 
However, average SBP and DBP were not reduced as a 
consequence. This may indicate that increments in blood 
pressure were blunted by the increase in antihypertensive 
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prescription. Nevertheless, optimal control was not achieved 
and increasing doses and/or number of antihypertensive drugs 
were probably indicated.
Different figures were obtained when analyzing the 
proportion of patients receiving lipid-lowering drugs in 
the initial evaluation. Despite the fact that mean total 
and LDL cholesterol levels were high and the population 
studied had been followed, on average, for more than 4 
years since the renal transplant, only 3% of the patients 
were on statins at that time. This is a matter of concern, 
particularly if we consider the data from the ALERT study, 
which suggest that cardiovascular prevention obtained with 
statins is more effective when instituted early [within 2 
years of transplantation]. After 12 months, the number of 
patients on lipid-lowering therapy was markedly increased 
(about 15-fold). Consequently, TC and TG levels were 
significantly reduced in 12 months. Average LDL levels 
presented a non-significant decrease and the relatively small 
proportion of patients with available LDL levels in medical 
records at the initial evaluation probably contributed to 
that. However, there was a significant 25% decrease in LDL 
levels in the subgroup of patients starting statins6-8 after 
the implementation of our strategy. The magnitude of the 
effect of lipid-lowering therapy is comparable to that seen 
in both general and RTR populations receiving statins. If 
we extrapolate the long-term follow-up data obtained to 
the general population, the LDL decrements seen in our 
study would promote a reduction of approximately 25% in 
the relative risk for coronary events in 5 years6. However, 
despite these encouraging results and, as previously observed 
in other RTR studies8,12, we must emphasize that average 
LDL levels remained above the recommended levels by the 
end of the study. The underestimation of the importance 
of controlling lipid levels can be appreciated if we analyze 
plasma lipid evaluation. Although 80% of patients were 
screened for dyslipidemia in some way during the year before 
the beginning of data collection, only a small proportion of 
patients presented a complete lipid profile in their charts. 
Since the complete lipid profile is essential for cardiovascular 
risk management, we assume that the majority of patients 
were not properly evaluated and/or treated for dyslipidemia. 
After 12 months this pattern changed significantly. In spite of 
a decrease in the total amount of patients being evaluated for 
dyslipidemia, the proportion of patients with a complete lipid 
profile was increased from 27% to 48%. This new pattern 
of evaluation, although sub-optimal, suggested a growing 
concern of attending physicians towards the analysis of lipid 
profile and, by extension, of cardiovascular risk.
At the initial evaluation, in spite of the fact that 58% of 
patients could be classified as high risk, only 29% of the total 
sample (37% of high-risk patients) was receiving aspirin. These 
numbers are very unsatisfactory, since primary and secondary 
prevention of cardiovascular events with antiplatelet therapy 
is supported by several studies in the general population 
and clinical guidelines clearly recommend antiplatelet drugs 
for patients with established atherosclerotic disease and/or 
diabetes, regardless of their renal function status24-26. After 
12 months of this study, the proportions of patients receiving 
aspirin in the whole sample and in the high-risk subgroup 
almost doubled. Once again, assuming that data from the 
general population can be applied to RTR, the increment in 
secondary prevention seen in our study will reduce non-fatal 
myocardial infarction and cardiac death in 16% and non-
fatal ischemic stroke risk in 25% for patients with previous 
cardiovascular events26. 
In opposition to the significant improvement obtained 
in matters related to drug prescription and physician 
compliance (e.g. lipid profile evaluation), our strategy was 
not effective when changes in lifestyle were analyzed. BMI 
reduction and tobacco dependence control were poorly 
achieved. While unaccounted factors, such as prescribed 
immunosuppressants, may have played a role on BMI stability 
above recommended levels, it is well known that obesity 
control in RTR is extremely difficult and more successful 
when intensified in the immediate post-transplant period27,28. 
There are no interventions on tobacco dependence 
specifically designed for RTR29. In our study, patients were 
directed to a local program that was not specific for RTR and 
not linked to the team of attending physicians. Difficulties in 
implementing lifestyle modifications are a rule in the general 
population and that is, perhaps, magnified in RTR due to 
factors that include poorer exercise capacity, prescription of a 
long list of drugs per patient and the inevitable imposition of 
a busy schedule. Thus, longer-term, more specific programs, 
connected to routine medical appointments, might generate 
more effective results. 
All modifications observed occurred in a relatively short 
period of time after the initiation of our intervention, at 
relevant magnitudes. Furthermore, the population studied 
was being followed for an average of 4 years and no abrupt 
changes related to cardiovascular risk factor control other 
than our protocol was implemented in the transplant unit. 
We employed a quasi-experimental approach, by which 
observations were made before and after interventions30. 
That modality was chosen as ethical and logistic issues 
did not allow us to obtain an adequate control group. 
As recommendations about proper cardiovascular risk 
management had to be made to the entire team of attending 
physicians of the renal transplant unit, it was not feasible 
to select a group of patients to whom the evidence-based 
care would not be offered. It has been demonstrated 
that more pronounced improvements observed after 
a specific intervention such as the one presented here 
confirm that changes are attributable to the intervention 
itself. Concurrent factors are minimized as the impact of 
these changes increases. An example of pretest/posttest 
study without controls is the GAP project carried out in 
Michigan13. Acute myocardial infarction quality-of-care 
measures were assessed among eligible patients at baseline 
and after the introduction of clinical tools designed to 
improve them. Significant improvements were detected 
during hospitalization and at the moment of hospital 
discharge13,30. Thus, although changes detected may be a 
consequence of chance, it is reasonable to conclude that 
they were a direct result of our strategy.
It is known that clinical guidelines for cardiovascular 
management in the general population are not properly 
applied to all eligible patients13 and a similar pattern was 
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verified in our institution concerning RTR. The strategy 
here described for cardiovascular risk factor identification 
and control, which is inexpensive and easily implemented, 
demonstrates that much can still be done for RTR. We believe 
that results, however, would be potentiated if coordinated 
actions, involving physicians of different specialties, nurses, 
nutrition experts, psychologists and social workers, were set 
in place. Greater, long-lasting benefits, at a relatively low cost, 
would certainly be granted to RTR, as already demonstrated 
in the general population13. 
In summary, we established a cost-effective, relatively 
simple strategy to optimize cardiovascular risk factor profile 
evaluation and treatment for RTR in a renal transplant unit 
of São Paulo, Brazil. Considering the impact of comparable 
approaches in the general population, we anticipate marked 
benefits for long-term graft function and life expectancy in 
the specific group of patients studied herein. 
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